Treatment of Linear IgA Bullous Dermatosis in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
This protocol applies to patients with Linear IgA bullous dermatosis who have glucose-6-phosphate dehydrogenase (G6PD) deficiency, dapsone hypersensitivity, severe anaemia, or organ failure — conditions that preclude standard first-line agents due to significant potential side effects.
In this clinical scenario, a systemic corticosteroid-based approach serves as the primary treatment option. The complete regimen — including agent selection, sequencing, and monitoring guidance — is available in the full protocol.
References
DOI: 10.1111/jdv.19880Digital
Systemic corticosteroids may be a primary option when dapsone or sulfonamides cannot be used because of their significant potential side effects (for example, in G6PD deficiency), dapsone hypersensitivity, severe anaemia or organ failure.
View source ↗